Diaceutics PM Readiness 2015 report provides a snapshot of how commercially ready pharma is for personalized medicine. It shows how the competitive landscape has changed since its last report in 2010. Download the report here: http://www.diaceutics.com/pm-readiness-2015

1. You can read the Diaceutics Pharma Readiness for Personalized Medicine Report in more
detail at the following link: http://www.diaceutics.com/pm-readiness-2015
Diaceutics PM Readiness 2015 report provides a snapshot of how
commercially ready pharma is for personalized medicine. It shows
how the competitive landscape has changed since its last report in
2010.
SUBJECTS
12PHARMA
COMPANIES
EXAMINED
COMPANION DIAGNOSTICS
76
PERSONALIZED THERAPIES IN
PIPELINE
NO. of PM THERAPIES
IN PHASE 3
TARGET THERAPIES
MORE THERAPIES THAN
IN 2010
ARE NOW CLASSFIED AS
TARGETED THERAPIES
TIMESCALE
2014
2010
TRACKS COMPETITIVE
CHANGES
FROM
2010-2014
DATA SETS
OVER
8000
DATA SETS
USED
WHICH COMPANIES HAVE DONE WELL?
*Disrupters - companies which have demonstrated the ability to competitively reshape therapy areas via personalized medicine;
Breakaway - companies that have made proactive investments positioning themselves to migrate operating models and corporate structure to
successfully commercialize targeted therapies; and
Followers - companies most likely to respond to the actions of others with little central PM management and little commercial experience with PM
therapies.
53therapies retrofitted
with biomarkers
7
therapies linked
to FDA
Approved Cdx
launched
KEY HEADLINES BY NUMBERS
2X
PERSONALIZED THERAPIES ON THE
MARKET
% of PM THERAPIES
ON THE MARKET3X
ROCHE THE MOST CDX DEALS
2010-2014
THE HIGHEST % OF PM
ONCOLOGY THERAPIES
AND
WHICH ONCOLOGY PM THERAPIES HAVE
HAD THE HIGHEST SALES?
HERCEPTIN
RITUXAN
GLEEVAC
WHO IS COMMERICALLY READY FOR PERSONALIZED MEDICINE?
DISRUPTORS
BREAKAWAY
FOLLOWERS
JANSSEN
ROCHE
NOVARTIS
ASTRAZENECA
GSK
PFIZER
BMS
BOEHRINGER INGELHEIM
MERCK
AMGEN
SANOFIELI LILLY
SANOFI
THE HIGHEST % OF PM THERAPIES
IN PHASE III/REGISTRATION